Tags

Type your tag names separated by a space and hit enter

The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
Pharmacoepidemiol Drug Saf. 2008 Oct; 17(10):953-61.PD

Abstract

PURPOSE

To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins.

METHODS

Patients prescribed a statin that they had not used before were selected from the Saskatchewan Health Databases (SHD) and followed up from 1 July 2003 until 31 March 2005.

RESULTS

We studied 10,384 patients on rosuvastatin and 14,854 taking other statins. Two cases of myopathy were identified (one on rosuvastatin, one on another statin). The relative risk (RR) of myopathy in patients currently taking rosuvastatin compared with other statins was 1.31 (95% confidence interval [CI]: 0.13-13.41). Two cases of rhabdomyolysis were detected among current rosuvastatin users (incidence: 2.9 [95% CI: 0.8-10.7] per 10 000 person-years). No cases of acute liver injury occurred among rosuvastatin patients. Seventeen cases of acute renal failure were identified (five among rosuvastatin users, 12 taking other statins). The RR of acute renal failure in current rosuvastatin users compared with other statins was 0.49 (95% CI: 0.16-1.50). We identified 285 deaths during the study period (87 among rosuvastatin users, 198 taking other statins). The RR of death in current rosuvastatin users compared with other statins was 0.42 (95% CI: 0.32-0.57).

CONCLUSIONS

We found no evidence that patients prescribed rosuvastatin were at greater risk of the study outcomes than patients prescribed other statins. There was no evidence of increased mortality among patients taking rosuvastatin, even after allowing for age, sex and prior statin use.

Authors+Show Affiliations

Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain. lagarcia@ceife.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18425987

Citation

García-Rodríguez, Luis Alberto, et al. "The Safety of Rosuvastatin in Comparison With Other Statins in Over 25,000 Statin Users in the Saskatchewan Health Databases." Pharmacoepidemiology and Drug Safety, vol. 17, no. 10, 2008, pp. 953-61.
García-Rodríguez LA, González-Pérez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008;17(10):953-61.
García-Rodríguez, L. A., González-Pérez, A., Stang, M. R., Wallander, M. A., & Johansson, S. (2008). The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiology and Drug Safety, 17(10), 953-61. https://doi.org/10.1002/pds.1602
García-Rodríguez LA, et al. The Safety of Rosuvastatin in Comparison With Other Statins in Over 25,000 Statin Users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008;17(10):953-61. PubMed PMID: 18425987.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. AU - García-Rodríguez,Luis Alberto, AU - González-Pérez,Antonio, AU - Stang,Mary Rose, AU - Wallander,Mari-Ann, AU - Johansson,Saga, PY - 2008/4/22/pubmed PY - 2009/5/5/medline PY - 2008/4/22/entrez SP - 953 EP - 61 JF - Pharmacoepidemiology and drug safety JO - Pharmacoepidemiol Drug Saf VL - 17 IS - 10 N2 - PURPOSE: To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins. METHODS: Patients prescribed a statin that they had not used before were selected from the Saskatchewan Health Databases (SHD) and followed up from 1 July 2003 until 31 March 2005. RESULTS: We studied 10,384 patients on rosuvastatin and 14,854 taking other statins. Two cases of myopathy were identified (one on rosuvastatin, one on another statin). The relative risk (RR) of myopathy in patients currently taking rosuvastatin compared with other statins was 1.31 (95% confidence interval [CI]: 0.13-13.41). Two cases of rhabdomyolysis were detected among current rosuvastatin users (incidence: 2.9 [95% CI: 0.8-10.7] per 10 000 person-years). No cases of acute liver injury occurred among rosuvastatin patients. Seventeen cases of acute renal failure were identified (five among rosuvastatin users, 12 taking other statins). The RR of acute renal failure in current rosuvastatin users compared with other statins was 0.49 (95% CI: 0.16-1.50). We identified 285 deaths during the study period (87 among rosuvastatin users, 198 taking other statins). The RR of death in current rosuvastatin users compared with other statins was 0.42 (95% CI: 0.32-0.57). CONCLUSIONS: We found no evidence that patients prescribed rosuvastatin were at greater risk of the study outcomes than patients prescribed other statins. There was no evidence of increased mortality among patients taking rosuvastatin, even after allowing for age, sex and prior statin use. SN - 1099-1557 UR - https://www.unboundmedicine.com/medline/citation/18425987/The_safety_of_rosuvastatin_in_comparison_with_other_statins_in_over_25000_statin_users_in_the_Saskatchewan_Health_Databases_ L2 - https://doi.org/10.1002/pds.1602 DB - PRIME DP - Unbound Medicine ER -